Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.